Key result
Subsegmental PE shows no difference in VTE recurrence risk versus central PE in lung cancer.
Why the study?
The clinical significance of lung cancer-associated subsegmental pulmonary embolism remains unclear.
Does subsegmental pulmonary embolism carry a different risk of VTE recurrence and all-cause death compared to more central pulmonary embolism in patients with lung cancer?
Cohort (n=902)
Does subsegmental pulmonary embolism carry a different risk of VTE recurrence and all-cause death compared to more central pulmonary embolism in patients with lung cancer?
In patients with lung cancer, subsegmental pulmonary embolism carries a similar risk of VTE recurrence and death as more central PE, and anticoagulation significantly reduces VTE recurrence in the subsegmental PE group.
Answers are grounded in this paper and cite their sources.
Comparable recurrence risk suggests subsegmental PE may not warrant distinct management in lung cancer; leaves open optimal anticoagulation strategies pending randomized data.
The clinical significance of lung cancer-associated subsegmental pulmonary embolism (PE) remains unclear. This study retrospectively included 902 patients with lung cancer-associated PE (160 subsegmental PE, 742 more central PE). Cox proportional hazards regression was used to assess the risk of all-cause death. Fine-Gray tests and competing risk models were applied to evaluate the risks (hazard ratio [HR] [95% confidence interval]) of venous thromboembolism (VTE) recurrence and major bleeding. All-cause death was treated as a competing event for both VTE recurrence and major bleeding. Compared with the more central PE group, the subsegmental PE group showed no significant differences in the adjusted risks of VTE recurrence (HR 0.99 [0.62–1.57], p = 0.95) and all-cause death (HR 0.83 [0.52–1.34], p = 0.45), and this finding was consistent across subgroups. Compared with patients with subsegmental PE without anticoagulation, those with anticoagulation had a lower adjusted risk of VTE recurrence (HR 0.16 [0.05–0.53], p = 0.003). The adjusted risks of major bleeding (HR 0.30 [0.05–1.70], p = 0.18) and all-cause death (HR 0.43 [0.13–1.42], p = 0.17) did not reach statistical significance. Independent predictors of VTE recurrence included symptomatic deep vein thrombosis (HR 2.71 [1.63–4.52], p < 0.001), tumor–node–metastasis stage (HR 2.07 [1.19–3.60], p = 0.010), EGFR mutations (HR 0.62 [0.39–0.98], p = 0.041), and anticoagulation (HR 0.32 [0.20–0.52], p < 0.001). The risk of recurrent VTE is not miniscule in patients with lung cancer-associated subsegmental PE.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) conducted a cohort in Lung cancer-associated pulmonary embolism (n=902). Subsegmental pulmonary embolism vs. More central pulmonary embolism was evaluated on VTE recurrence (HR 0.99, 95% CI 0.62-1.57, p=0.95). Subsegmental pulmonary embolism in lung cancer patients showed no significant difference in VTE recurrence risk compared to more central pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: